Home » Stocks » CRTX

Cortexyme, Inc. (CRTX)

Stock Price: $36.77 USD 2.44 (7.11%)
Updated May 14, 2021 4:00 PM EDT - Market closed
Market Cap 1.09B
Revenue (ttm) n/a
Net Income (ttm) -82.76M
Shares Out 29.59M
EPS (ttm) -2.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $36.77
Previous Close $34.33
Change ($) 2.44
Change (%) 7.11%
Day's Open 34.50
Day's Range 33.92 - 37.33
Day's Volume 139,156
52-Week Range 26.66 - 58.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it belie...

6 days ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme to Present at the BofA Securities 2021 Healthcare Conference on May 11, 2021

1 week ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a gr...

1 month ago - Business Wire

New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX). Such investors are ...

1 month ago - Newsfile Corp

NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX).  Such investors are advised to co...

2 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer's and other degenerative diseases, today announced Chris Low...

2 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer's and other degenerative diseases, announced that it has par...

2 months ago - Business Wire

Getting a big headache watching large-cap S&P 500 stocks lose steam? Small-cap stocks are giving investors a new way to make big money.

Other stocks mentioned: AGTC, ATOM, AYTU, CODX, DVAX, SRNE
2 months ago - Investors Business Daily

Following the review of hepatic adverse events, the FDA has instituted a partial clinical hold impacting the open-label extension (OLE) phase of Phase 2/3 GAIN trial of Cortexyme Inc (NASDAQ: CRTX) eval...

3 months ago - Benzinga

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (NASDAQ: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer's and other degenerative diseases, received a letter from th...

3 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease on schedule to be announced in Q4 2021 and a pipeline of therapeu...

3 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer's and other degenerative diseases...

3 months ago - Business Wire

CRTX thinks that a bacteria causes Alzheimer's, and it has research to back up that hypothesis. A Phase 3 trial will yield toppling data in Dec 2021, and they have enough cash.

4 months ago - Seeking Alpha

Investors need to pay close attention to Cortexyme (CRTX) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer's and other degenerative diseases...

5 months ago - Business Wire

Investors need to pay close attention to Cortexyme (CRTX) stock based on the movements in the options market lately.

5 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering potential therapeutics for Alzheimer's and other degenerative diseases...

6 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer's and other degenerative diseases...

6 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer's and other degenerative diseases...

6 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX) today announced that its GAIN Trial for Alzheimer’s disease (AD) has exceeded its enrollment target of 570 patients. GAIN is ...

7 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc.

8 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc.

8 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc.

8 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc.

9 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc.

9 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc.

9 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with Alzheimer’s...

9 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc.

9 months ago - Business Wire

The 2020 year is practically halfway done, and this has really been the year of the biotech.

Other stocks mentioned: ACAD, BIIB, BTAI, ITCI, NBIX, SAGE, ZYNE
11 months ago - 24/7 Wall Street

Cortexyme: A New Approach To Defeat Alzheimer's Disease

11 months ago - Seeking Alpha

A promising new approach could potentially yield a new drug providing hope for millions of Alzheimer's patients worldwide.

1 year ago - The Motley Fool

Cortexyme (NASDAQ: CRTX) is a clinical stage bio-pharmaceutical company working on Alzheimer’s and other degenerative diseases. The company currently has one molecule in its pipeline, called COR388, tha...

1 year ago - Forbes

Karuna Therapeutics, NextCure, and Cortexyme aren’t household names when it comes to investors looking at initial public offerings (IPOs), but they’ve been generating big-time returns for investors who ...

Other stocks mentioned: BYND, IGMS, INMD, KRTX, NXTC, PLMR, SWAV ...
1 year ago - ETF Trends

2019 was one of the busiest years for IPOs, and the calendar was packed with big tech unicorns and popular consumer brands. Here are some of the hottest market debuts we saw this year.

Other stocks mentioned: BYND, LYFT, RVLV, UBER
1 year ago - Zacks Investment Research

About CRTX

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease. Cortexyme, Inc. has a partnership with Parkinson Study Group. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Industry
Biotechnology
IPO Date
May 9, 2019
Stock Exchange
NASDAQ
Ticker Symbol
CRTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for Cortexyme stock is "Buy." The 12-month stock price forecast is 71.29, which is an increase of 93.88% from the latest price.

Price Target
$71.29
(93.88% upside)
Analyst Consensus: Buy